Credit: Melanie Leveridge
A new SLAS Discovery review article by GlaxoSmithKline researchers in the U.S. and U.K. offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.
While high-throughout screening (HTS) remains a mainstay in drug discovery, other approaches have emerged or evolved in the past decade that offer complementary strengths and weaknesses, and are increasingly applied in combination with, or in lieu of, HTS. Great success often can be achieved by combining different approaches in an integrated manner.
Leveridge et al. survey the landscape of lead discovery tactics that researchers use today and explain how this toolbox of approaches is evolving as new science emerges, such as in the areas of complex cellular models and computational techniques. Case studies illustrate how integration of techniques like DNA-encoded library screening (ELT) and HTS, phenotypic and target-based screening, and virtual screening (VS) with experimental approaches can lead to successful outcomes and provide insights and synergies that would never have been obtained through one technique alone.
###
"Integration of Lead Discovery Tactics and the Evolution of the Lead Discovery Toolbox" can be accessed for free for a limited time at http://journals.sagepub.com/doi/full/10.1177/2472555218778503. For more information about SLAS and its journals, visit http://www.slas.org/journals.
About our Society and Journals
SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).
SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).
Follow SLAS on Twitter at @SLAS_Org.
Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.
Follow SLAS on YouTube at SLASvideo.
Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).
Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).
Media Contact
Nan Hallock
[email protected]
630-256-7527 x106
@SLAS_Org
https://www.slas.org/
Related Journal Article
http://dx.doi.org/10.1177/2472555218778503
